Prenosis secures $20M BARDA contract & $20M Series A funding, advancing innovation in critical care diagnostics & therapeutics.

Prenosis, a cutting-edge technology company focusing on biology-based diagnostics and therapeutics for critical care conditions, has recently made significant progress through its latest fundraising endeavors in Chicago. The company, which aims to revolutionize healthcare through integrated solutions, unveiled two key announcements on January 29, 2026. This successful round of funding is set to accelerate innovation in the field, with a focus on developing advanced diagnostics and therapies to address critical care needs. Keep an eye on Prenosis as they continue to drive forward in this essential sector.